Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) Research & Development (2016 - 2025)

Capricor Therapeutics has reported Research & Development over the past 15 years, most recently at $23.2 million for Q4 2025.

  • Quarterly results put Research & Development at $23.2 million for Q4 2025, up 58.94% from a year ago — trailing twelve months through Dec 2025 was $84.4 million (up 68.96% YoY), and the annual figure for FY2025 was $84.5 million, up 69.02%.
  • Research & Development for Q4 2025 was $23.2 million at Capricor Therapeutics, up from $20.4 million in the prior quarter.
  • Over the last five years, Research & Development for CAPR hit a ceiling of $23.2 million in Q4 2025 and a floor of $2.5 million in Q3 2021.
  • Median Research & Development over the past 5 years was $9.4 million (2023), compared with a mean of $10.3 million.
  • Peak annual rise in Research & Development hit 185.68% in 2021, while the deepest fall reached 4.92% in 2021.
  • Capricor Therapeutics' Research & Development stood at $4.3 million in 2021, then soared by 46.17% to $6.2 million in 2022, then soared by 58.86% to $9.9 million in 2023, then skyrocketed by 47.16% to $14.6 million in 2024, then surged by 58.94% to $23.2 million in 2025.
  • The last three reported values for Research & Development were $23.2 million (Q4 2025), $20.4 million (Q3 2025), and $22.0 million (Q2 2025) per Business Quant data.